Pathway Enrichment Analysis

Pathway Enrichment Analysis designates computational methods that identify biological pathways disproportionately represented among a set of genes, proteins, or metabolites derived from experimental data, enabling interpretation of high-dimensional omics results by linking molecular changes to functional biological processes. Rather than analysing individual genes in isolation, pathway enrichment approaches map altered features onto curated pathway databases such as KEGG, Reactome, or Gene Ontology.

The biopharmaceutical industry widely uses pathway enrichment analysis in target discovery, mechanism of action studies, biomarker development, and translational research, providing systems-level insights guiding hypothesis generation and therapeutic prioritisation. Transcriptomic profiling of tumour biopsies before and after treatment may reveal enrichment of interferon signalling, cell cycle regulation, or apoptosis pathways, indicating how therapies modulate disease biology. Enrichment outputs support identification of combination strategies by highlighting compensatory pathway activation that may drive resistance. Technical considerations include selection of appropriate background gene sets, controlling for multiple hypothesis testing, and ensuring pathway annotations remain current. As multi-omics datasets grow and precision medicine demands deeper mechanistic understanding, pathway enrichment analysis continues serving as an essential interpretive framework converting complex molecular datasets into actionable biological insights.